Dual Inhibition of ID1 and ID3 in Targeting Pulmonary Fibrosis
Idiopathic pulmonary fibrosis remains one of the most challenging respiratory diseases to treat, however new strategies that directly interrupt the cellular drivers of fibrosis are urgently needed.